JP2017522292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522292A5 JP2017522292A5 JP2016574898A JP2016574898A JP2017522292A5 JP 2017522292 A5 JP2017522292 A5 JP 2017522292A5 JP 2016574898 A JP2016574898 A JP 2016574898A JP 2016574898 A JP2016574898 A JP 2016574898A JP 2017522292 A5 JP2017522292 A5 JP 2017522292A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic composition
- less
- composition according
- ophthalmic
- muscarinic antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 37
- 239000003149 muscarinic antagonist Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000009745 Eye Disease Diseases 0.000 claims 3
- 229930006677 A03BA01 - Atropine Natural products 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- 229960000396 Atropine Drugs 0.000 claims 2
- 229960002028 Atropine Sulfate Drugs 0.000 claims 2
- JPKKQJKQTPNWTR-CHYDPLAESA-N CHEMBL3182372 Chemical compound O.OS(O)(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1.O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-CHYDPLAESA-N 0.000 claims 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 2
- 208000001491 Myopia Diseases 0.000 claims 2
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 2
- JACRWUWPXAESPB-QMMMGPOBSA-N Tropic acid Natural products OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 230000004515 progressive myopia Effects 0.000 claims 2
- 229960002646 scopolamine Drugs 0.000 claims 2
- ATKYNAZQGVYHIB-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate Chemical compound C1C(N2)CCC2CC1OC(=O)C(CO)C1=CC=CC=C1 ATKYNAZQGVYHIB-UHFFFAOYSA-N 0.000 claims 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 1
- HGWPFSBHDACWNL-LZYIFBDPSA-N CHEMBL2146145 Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2([O-])C)C(=O)C(CO)C1=CC=CC=C1 HGWPFSBHDACWNL-LZYIFBDPSA-N 0.000 claims 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 claims 1
- 229940054534 Ophthalmic Solution Drugs 0.000 claims 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N Pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 claims 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N Tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 claims 1
- 229950010917 atropine oxyde Drugs 0.000 claims 1
- -1 cyclopentrate Chemical compound 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229960000857 homatropine Drugs 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000002997 ophthalmic solution Substances 0.000 claims 1
- 229960004633 pirenzepine Drugs 0.000 claims 1
- 230000002335 preservative Effects 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 229960004919 procaine Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- HEMHJVSKTPXQMS-DYCDLGHISA-M sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229960004791 tropicamide Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N water-d2 Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims 1
Claims (25)
- 約０．００１ｗｔ％から約０．０５ｗｔ％のムスカリンアンタゴニストと重水素化水を含む、約４．２〜約７．９のｐＤの眼科用組成物。
- ムスカリンアンタゴニストは、アトロピン、硫酸アトロピン、ノルアトロピン、アトロピン−Ｎ−オキシド、トロピン、トロパ酸、ヒヨスチン、スコポラミン、トロピカミド、シクロペントレート、ピレンゼピン、ホマトロピン、またはこれらの組み合わせを含む、請求項１に記載の眼科用組成物。
- ムスカリンアンタゴニストはアトロピンまたは硫酸アトロピンである、請求項２に記載の眼科用組成物。
- 眼科用組成物は、保存条件下で長期間の経過後に、約７．３未満、約７．２未満、約７．１未満、約７未満、約６．８未満、約６．５未満、約６．４未満、約６．３未満、約６．２未満、約６．１未満、約６未満、約５．９未満、約５．８未満、約５．２未満、または約４．８未満の１つのｐＤを有する、請求項１−３のいずれか１つに記載の眼科用組成物。
- 眼科用組成物は、保存条件下で長期間の経過後に、初期の濃度に基づいて、少なくとも約８０％、少なくとも約８５％、少なくとも約９０％、少なくとも約９３％、少なくとも約９５％、少なくとも約９７％、少なくとも約９８％、または、少なくとも約９９％のムスカリンアンタゴニストの１つを含む、請求項１−４のいずれか１つに記載の眼科用組成物。
- 眼科用組成物は、保存条件下で長期間の経過後に、少なくとも８０％、少なくとも８５％、少なくとも９０％、少なくとも９３％、少なくとも９５％、少なくとも９７％、少なくとも９８％、または少なくとも９９％の１つの効能をさらに有する、請求項１−５のいずれか１つに記載の眼科用組成物。
- 保存条件は約２°Ｃから約１０°Ｃ、または約１６°Ｃから約２６°Ｃの保存温度を有する、請求項１−６のいずれか１つに記載の眼科用組成物。
- ムスカリンアンタゴニストは、約０．００１ｗｔ％から約０．０４ｗｔ％、約０．００１ｗｔ％から約０．０３ｗｔ％、約０．００１ｗｔ％から約０．０２５ｗｔ％、約０．００１ｗｔ％から約０．０２ｗｔ％、約０．００１ｗｔ％から約０．０１ｗｔ％、約０．００１ｗｔ％から約０．００８ｗｔ％、または約０．００１ｗｔ％から約０．００５ｗｔ％の１つの濃度で組成物中に存在する、請求項１−７のいずれか１つに記載の眼科用組成物。
- 眼科用組成物は、モル浸透圧濃度調整剤、保存剤、緩衝剤、等張化剤、またはこれらの組み合わせをさらに含む、請求項１−８のいずれか１つに記載の眼科用組成物。
- 眼科用組成物は、５０％未満、４０％未満、３０％未満、２０％未満、１０％未満、または５％未満の１つの投与量間のムスカリンアンタゴニストの濃度変化を有する、請求項１−９のいずれか１つに記載の眼科用組成物。
- 眼科用組成物は、プロカインとベナクチジン、またはその薬学的に許容可能な塩を本質的に含まない、請求項１−１０のいずれか１つに記載の眼科用組成物。
- 眼科用組成物はさらにｐＤ調整剤を含む、請求項１−１１のいずれか１つに記載の眼科用組成物。
- ｐＤ調整剤はＤＣｌ、ＮａＯＤ、ＣＤ３ＣＯＯＤ、またはＣ６Ｄ８Ｏ７を含む、請求項１２に記載の眼科用組成物。
- 眼科用組成物は、５％未満のＨ２Ｏ、４％未満のＨ２Ｏ、３％未満のＨ２Ｏ、２％未満のＨ２Ｏ、１％未満のＨ２Ｏ、０．５％未満のＨ２Ｏ、０．１％未満のＨ２Ｏ、または、０％のＨ２Ｏの１つを含む、請求項１−１３のいずれか１つに記載の眼科用組成物。
- 眼科用組成物は溶液である、請求項１−１４のいずれか１つに記載の眼科用組成物。
- 眼科用組成物は注射可能な製剤として処方されない、請求項１−１５のいずれか１つに記載の眼科用組成物。
- 眼科用組成物は眼の疾病の処置のための眼科用溶液として処方される、請求項１−１６のいずれか１つに記載の眼科用組成物。
- 眼の疾病または疾患は、近視前症、近視、または近視の進行である、請求項１−１７のいずれか１つに記載の眼科用組成物。
- 有効な量の請求項１−１８の眼科用組成物を必要としている個体の目に投与することを含む、眼の疾病または疾患の処置のための薬剤の製造における眼科用組成物の使用。
- 眼科用組成物は最初の使用の前に約２°Ｃから約１０°Ｃで保存される、請求項１９に記載の使用。
- 眼科用組成物は最初の使用の後に約１６°Ｃから約２６°Ｃで保存される、請求項１９に記載の使用。
- 眼の疾病または疾患は近視前症、近視、または近視の進行である、請求項１９に記載の使用。
- 眼科用組成物は局所的に投与される、請求項１９に記載の使用。
- 眼科用組成物は注入によって投与される、請求項１９に記載の使用。
- 眼科用組成物は、眼科用組成物を含む点眼瓶によって投与される、請求項１９に記載の使用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020014108A JP7505888B2 (ja) | 2014-06-24 | 2020-01-30 | 眼科用組成物 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016502P | 2014-06-24 | 2014-06-24 | |
| US62/016,502 | 2014-06-24 | ||
| US201462096433P | 2014-12-23 | 2014-12-23 | |
| US62/096,433 | 2014-12-23 | ||
| US201562151926P | 2015-04-23 | 2015-04-23 | |
| US62/151,926 | 2015-04-23 | ||
| US14/726,139 US9421199B2 (en) | 2014-06-24 | 2015-05-29 | Ophthalmic composition |
| US14/726,139 | 2015-05-29 | ||
| PCT/US2015/037249 WO2015200361A1 (en) | 2014-06-24 | 2015-06-23 | Ophthalmic composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020014108A Division JP7505888B2 (ja) | 2014-06-24 | 2020-01-30 | 眼科用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522292A JP2017522292A (ja) | 2017-08-10 |
| JP2017522292A5 true JP2017522292A5 (ja) | 2018-08-09 |
| JP6678362B2 JP6678362B2 (ja) | 2020-04-08 |
Family
ID=54868660
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574898A Active JP6678362B2 (ja) | 2014-06-24 | 2015-06-23 | 眼科用組成物 |
| JP2020014108A Active JP7505888B2 (ja) | 2014-06-24 | 2020-01-30 | 眼科用組成物 |
| JP2022003408A Pending JP2022062045A (ja) | 2014-06-24 | 2022-01-12 | 眼科用組成物 |
| JP2023180519A Pending JP2024050526A (ja) | 2014-06-24 | 2023-10-19 | 眼科用組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020014108A Active JP7505888B2 (ja) | 2014-06-24 | 2020-01-30 | 眼科用組成物 |
| JP2022003408A Pending JP2022062045A (ja) | 2014-06-24 | 2022-01-12 | 眼科用組成物 |
| JP2023180519A Pending JP2024050526A (ja) | 2014-06-24 | 2023-10-19 | 眼科用組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (11) | US9421199B2 (ja) |
| EP (3) | EP3689350A1 (ja) |
| JP (4) | JP6678362B2 (ja) |
| KR (4) | KR102506109B1 (ja) |
| CN (3) | CN110638749A (ja) |
| BR (1) | BR112016030368B1 (ja) |
| CA (1) | CA2953363C (ja) |
| DK (1) | DK3160471T3 (ja) |
| ES (1) | ES2924243T3 (ja) |
| HR (1) | HRP20220972T1 (ja) |
| HU (1) | HUE059521T2 (ja) |
| IL (1) | IL249643B (ja) |
| LT (1) | LT3160471T (ja) |
| PL (1) | PL3160471T3 (ja) |
| PT (1) | PT3160471T (ja) |
| RS (1) | RS63486B1 (ja) |
| SG (3) | SG11201610682UA (ja) |
| SI (1) | SI3160471T1 (ja) |
| TW (2) | TW202412797A (ja) |
| WO (1) | WO2015200361A1 (ja) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2887923B1 (en) | 2012-08-24 | 2023-04-05 | Sun Pharmaceutical Industries Limited | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
| WO2016172712A2 (en) * | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| US10010502B2 (en) | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
| WO2016196367A1 (en) | 2015-05-29 | 2016-12-08 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| PT3373976T (pt) | 2015-11-10 | 2024-04-02 | Sun Pharmaceutical Ind Ltd | Formulações tópicas e suas utilizações |
| WO2017151657A1 (en) | 2016-02-29 | 2017-09-08 | Ocular Technologies Sarl | Topical cyclosporine-containing formulations and uses thereof |
| KR102578476B1 (ko) * | 2016-04-11 | 2023-09-13 | 유니버시티 오브 캔버라 | 레보도파, 항산화제 및 수성 담체를 포함하는 안과 조성물 |
| ES2929368T3 (es) * | 2016-05-25 | 2022-11-28 | Singapore Health Serv Pte Ltd | Composición acuosa que contiene atropina |
| AU2018224426B2 (en) * | 2017-02-21 | 2023-05-18 | Singapore Health Services Pte Ltd | Composition and method for preventing or delaying onset of myopia comprising atropine |
| JP7016880B2 (ja) * | 2017-03-23 | 2022-02-07 | シンガポール ヘルス サービシーズ ピーティーイー リミテッド | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 |
| ES2960921T3 (es) | 2017-03-27 | 2024-03-07 | Regeneron Pharma | Procedimiento de esterilización |
| CN110621298B (zh) * | 2017-05-11 | 2022-12-20 | 维卢玛有限公司 | 阿托品药物组合物 |
| SG11201911895XA (en) | 2017-06-10 | 2020-01-30 | Eyenovia Inc | Methods and devices for handling a fluid and delivering the fluid to the eye |
| CA3070556A1 (en) | 2017-07-20 | 2019-01-24 | Alan Laboratories, Inc. | Compositions and methods for treatment of myopia |
| WO2019104191A1 (en) * | 2017-11-21 | 2019-05-31 | Sydnexis, Inc. | Ophthalmic composition and delivery device thereof |
| CN112105320A (zh) | 2018-01-05 | 2020-12-18 | 犹他大学研究基金会 | 治疗近视进展 |
| CN110934869B (zh) * | 2018-09-25 | 2023-07-04 | 沈阳兴齐眼药股份有限公司 | 一种阿托品药物组合物和药盒产品 |
| CN114557955B (zh) * | 2018-09-25 | 2024-06-18 | 沈阳兴齐眼药股份有限公司 | 药物组合物、其制备方法和用途 |
| EP3701938B8 (en) | 2019-03-01 | 2024-02-21 | Medivis S.R.L. | Ophthalmic formulations based on atropine |
| WO2020219707A1 (en) * | 2019-04-24 | 2020-10-29 | Allergan, Inc. | Compositions and methods for treatment of ocular conditions |
| KR102308566B1 (ko) * | 2019-05-28 | 2021-10-05 | 서울대학교병원 | 녹내장 안약의 약물이상반응 진단 키트 |
| CA3146848A1 (en) * | 2019-07-11 | 2021-01-14 | University Of Utah Research Foundation | Multi-agent ocular formulations and treatment methods |
| JP2023502591A (ja) * | 2019-11-15 | 2023-01-25 | シルク テクノロジーズ、リミテッド | 絹由来タンパク質の安定した配合物 |
| US20230041788A1 (en) * | 2019-12-16 | 2023-02-09 | Sydnexis, Inc. | Ophthalmic compositions comprising d2o |
| CN111821259A (zh) * | 2020-07-14 | 2020-10-27 | 艾尔健康眼药(辽宁)有限公司 | 一种眼用药物组合物 |
| US11850249B2 (en) | 2020-10-05 | 2023-12-26 | Somerset Therapeutics, Llc | Methods of efficiently reducing intraocular pressure |
| KR102245533B1 (ko) * | 2020-11-02 | 2021-04-28 | 주식회사 지게차코리아 | 운송수단용 림 및 이의 제조방법 |
| AU2022212108A1 (en) * | 2021-01-28 | 2023-08-17 | Glaukos Corporation | Formulations |
| US20240139166A1 (en) * | 2021-02-04 | 2024-05-02 | Sydnexis, Inc. | Ophthalmic compositions for presbyopia |
| WO2022172089A1 (en) * | 2021-02-12 | 2022-08-18 | I Optima Ltd. | Compound, method and system for ophthalmic surgery |
| PE20241644A1 (es) * | 2021-03-16 | 2024-08-09 | Vyluma Inc | Envase multi-dosis para composiciones oftalmica |
| EP4088714A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| EP4088713A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| EP4426353A2 (en) * | 2021-11-05 | 2024-09-11 | Calm Water Therapeutics LLC | Methods for using bioadhesive and steric interactions of copolymers to minimize adverse effects |
| WO2023172240A1 (en) * | 2022-03-07 | 2023-09-14 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| US20230277521A1 (en) * | 2022-03-07 | 2023-09-07 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| WO2023171989A1 (ko) * | 2022-03-11 | 2023-09-14 | 주식회사 메디치바이오 | 안질환 예방 또는 치료용 약학 조성물 |
| WO2023215407A2 (en) * | 2022-05-03 | 2023-11-09 | Iview Therapeutics, Inc. | Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases |
| US20240033260A1 (en) * | 2022-07-26 | 2024-02-01 | The Chinese University Of Hong Kong | Low-concentration atropine for myopia prevention (lamp-2) study |
| WO2024091789A1 (en) * | 2022-10-26 | 2024-05-02 | Vyluma Inc. | Childhood atropine for myopia progression |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4382124B1 (en) | 1958-07-18 | 1994-10-04 | Rohm & Haas | Process for preparing macroreticular resins, copolymers and products of said process |
| NL284933A (ja) | 1961-10-31 | |||
| DE1518819B1 (de) | 1965-04-03 | 1969-12-04 | Basf Ag | Loesungsvermittler fuer pharmazeutische Zwecke |
| SE352811B (ja) | 1971-06-04 | 1973-01-15 | Pharmacia Ab | |
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4255415A (en) * | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| US4952586A (en) | 1982-08-27 | 1990-08-28 | The Regents Of The University Of California | Edrophonium-atropine composition and therapeutic uses thereof |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| DE3622399A1 (de) | 1986-07-01 | 1988-02-04 | Eberhardt Schlueter | Selbsttaetige injektionsvorrichtung sowie ampulle oder patrone fuer eine injektionsvorrichtung |
| US5147647A (en) | 1986-10-02 | 1992-09-15 | Sohrab Darougar | Ocular insert for the fornix |
| US4852582A (en) | 1987-09-11 | 1989-08-01 | Pell Donald M | Method and kit for measuring the effectiveness of bronchodilators |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| IL85312A (en) | 1988-02-03 | 1991-08-16 | Israel State | Injectable pharmaceutical compositions having improved stability |
| JP2617508B2 (ja) * | 1988-02-05 | 1997-06-04 | エーザイ株式会社 | 安定なジフェンヒドラミン含有水溶液 |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| FR2638428B1 (fr) | 1988-10-28 | 1990-12-28 | Transphyto Sa | Conditionnement pour liquides a epurer |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5496471A (en) | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
| US5259998A (en) | 1991-10-04 | 1993-11-09 | Chiron Ophthalmics, Inc. | Method for casting dissolvable ophthalmic shields in a mold |
| US5492689A (en) | 1991-11-19 | 1996-02-20 | The Center For Innovative Technology | Combined virustatic antimediator (COVAM) treatment of common colds |
| US5716952A (en) | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| US5505953A (en) | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5260000A (en) | 1992-08-03 | 1993-11-09 | Bausch & Lomb Incorporated | Process for making silicone containing hydrogel lenses |
| FR2702660B1 (fr) | 1993-03-17 | 1995-05-24 | Karl Simpson | Compositions thérapeutiques stabilisées et leur procédé de préparation. |
| US5840770A (en) | 1993-08-24 | 1998-11-24 | Hill Medical Corporation | Method of killing tumor cells |
| US5490938A (en) | 1993-12-20 | 1996-02-13 | Biopolymerix, Inc. | Liquid dispenser for sterile solutions |
| ES2171186T3 (es) | 1994-04-08 | 2002-09-01 | Atrix Lab Inc | Composiciones liquidas de difusion. |
| GB2293100A (en) | 1994-09-15 | 1996-03-20 | Medeva Europ Ltd | Pharmaceutical compositions with deuterium oxide |
| CZ285636B6 (cs) | 1995-02-07 | 1999-10-13 | Ústav Makromolekulární Chemie Av Čr | Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby |
| WO1997016192A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| FR2742357B1 (fr) | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
| JP2000509971A (ja) | 1996-04-10 | 2000-08-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 化学的シャペローンを用いる遺伝的欠陥の修正 |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US20030157187A1 (en) | 1996-12-02 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
| US20040136915A1 (en) | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
| FR2770843B1 (fr) | 1997-11-13 | 2000-01-14 | Lavipharm Lab | Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications |
| US6149670A (en) | 1999-03-11 | 2000-11-21 | Alsius Corporation | Method and system for treating cardiac arrest using hypothermia |
| US5976499A (en) | 1998-09-04 | 1999-11-02 | Johns Hopkins University | Macroscopic sweat test for cystic fibrosis |
| IN185228B (ja) | 1999-02-03 | 2000-12-09 | Bakulesh Mafatlal Dr Khamar | |
| WO2000069470A2 (en) | 1999-05-17 | 2000-11-23 | Aesgen, Inc. | Improved cellular uptake of bioactive agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
| CN1323595A (zh) | 2000-05-11 | 2001-11-28 | 朱卫国 | 用于青光眼的药物组合物 |
| US20050251254A1 (en) | 2000-06-02 | 2005-11-10 | Brady Daniel G | Method of implanting accommodating intraocular lenses |
| US20030195179A1 (en) | 2000-08-25 | 2003-10-16 | Shirou Sawa | Aqueous suspension preparations |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| WO2002096418A1 (en) | 2001-05-25 | 2002-12-05 | Valley Forge Pharmaceuticals | Pirenzepine ophthalmic gel |
| CN1206988C (zh) | 2002-05-10 | 2005-06-22 | 刘继东 | 硫酸阿托品眼用凝胶 |
| AU2004264974A1 (en) | 2003-08-15 | 2005-02-24 | Arius Two, Inc. | Adhesive bioerodible transmucosal drug delivery system |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US8333985B2 (en) | 2004-01-27 | 2012-12-18 | Warsaw Orthopedic, Inc. | Non-glycerol stabilized bone graft |
| US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US7659260B2 (en) | 2005-01-14 | 2010-02-09 | Eddie Francis Kadrmas | Tamponade compositions and methods for retinal repair |
| US8349351B2 (en) | 2005-02-04 | 2013-01-08 | Auburn University | Contact drug delivery system |
| US9238003B2 (en) | 2005-02-04 | 2016-01-19 | Auburn University | Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules |
| CN1939534B (zh) | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
| GB2423711B (en) * | 2005-10-24 | 2007-02-14 | Fortune Apex Dev Ltd | Method for preparing a pharmaceutical composition with enhanced mucoadhesion |
| US20100022495A1 (en) | 2005-11-01 | 2010-01-28 | President And Fellows Of Harvard College | Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis |
| US7767217B2 (en) | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| CN101049287A (zh) * | 2006-04-07 | 2007-10-10 | 财团法人长庚纪念医院 | 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法 |
| US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| JP2007308398A (ja) * | 2006-05-17 | 2007-11-29 | Chang Gung Memorial Hospital | 目薬、及びその製造方法 |
| US7691099B2 (en) | 2006-07-12 | 2010-04-06 | Ntk Enterprises, Inc. | Deuterated ocular solutions for LTK and other surgical eye procedures |
| US7745665B2 (en) | 2007-06-04 | 2010-06-29 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
| CN101327216A (zh) | 2007-06-22 | 2008-12-24 | 肖正连 | 一种硫酸阿托品眼用即型凝胶 |
| WO2009046967A1 (en) * | 2007-10-08 | 2009-04-16 | Fovea Pharmaceuticals Sa | Aqueous ophthalmic formulations |
| US7815605B2 (en) | 2007-11-28 | 2010-10-19 | Souter Steve R | Emergency medication pump injection system |
| CN101468214A (zh) * | 2007-12-27 | 2009-07-01 | 上海华捷视医疗设备有限公司 | 一种眼科手术用重水及其制备方法 |
| DK2110132T3 (da) | 2008-04-20 | 2014-04-28 | D2 Bioscience Group Ltd | Anvendelse af deuteriumoxid som elastasehæmmer |
| WO2010068281A2 (en) | 2008-12-11 | 2010-06-17 | Massachusetts Institute Of Technology | Contact lens drug delivery device |
| DE102009003942A1 (de) | 2009-01-07 | 2010-07-08 | D2O Biosience Group Ltd., Hamilton | Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges |
| WO2010083129A2 (en) * | 2009-01-13 | 2010-07-22 | The Regents Of The University Of California | Implantable delivery vehicle for ocular delivery of muscarinic antagonists |
| TW201043211A (en) | 2009-03-31 | 2010-12-16 | Johnson & Johnson Vision Care Inc | Punctal plugs |
| EP2464387A4 (en) * | 2009-08-12 | 2013-05-15 | Seros Medical Llc | DEUTERATED WATER SOLUTION AND RIBOFLAVIN FOR EXTENDED OXYGEN SINGULET LIFETIME IN THE TREATMENT OF OCULAR TISSUE AND METHOD OF USE |
| FR2950036B1 (fr) | 2009-09-11 | 2011-12-16 | Rexam Pharma La Verpilliere | Dispositif de distribution de liquide |
| FR2952040B1 (fr) | 2009-10-29 | 2011-12-30 | Rexam Pharma La Verpilliere | Dispositif de distribution de liquide sous forme de gouttes |
| WO2011098578A2 (en) | 2010-02-12 | 2011-08-18 | Bioneer A/S | Liposome system for ocular administration |
| JP2013525014A (ja) * | 2010-04-30 | 2013-06-20 | セロス メディカル， エルエルシー | 集学的方法を用いた眼組織の処置のための方法および装置 |
| TWI424663B (zh) | 2010-07-01 | 2014-01-21 | Joy Ride Tech Co Ltd | A motor with heat pipe |
| CN103124541B (zh) | 2010-07-15 | 2015-09-30 | 艾诺维亚股份有限公司 | 眼药物递送 |
| CN103118642B (zh) | 2010-07-15 | 2015-09-09 | 艾诺维亚股份有限公司 | 液滴生成装置 |
| TW201217533A (en) | 2010-08-04 | 2012-05-01 | Bayer Pharma AG | Genomics of actinoplanes utahensis |
| EP2675455A4 (en) * | 2011-02-18 | 2014-07-16 | M S Appasamy Associates | OPHTHALMIC COMPOSITION FOR DILATING PUPILS |
| CA2829040A1 (en) | 2011-03-03 | 2012-09-07 | Allergan, Inc. | Non-aqueous silicone-based ophthalmic formulations |
| CN107982211A (zh) | 2011-04-05 | 2018-05-04 | 奥普托索夫研究与发展有限公司 | 眼科治疗 |
| EP2707006B1 (en) | 2011-05-12 | 2019-07-03 | Foresight Biotherapeutics, Inc. | Stable povidone-iodine compositions with bromfenac |
| WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| TW201302244A (zh) | 2011-07-08 | 2013-01-16 | Univ Nat Chiao Tung | 載藥型隱形眼鏡及其製備方法 |
| EP2785335B8 (en) | 2011-11-29 | 2017-08-02 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of darier disease |
| US20170304152A1 (en) | 2012-02-01 | 2017-10-26 | Certa Dose, Inc. | Apparatuses, methods, and systems for delivering medication using medication kits |
| US9814729B2 (en) | 2012-03-14 | 2017-11-14 | The Regents Of The University Of California | Nerve agent antidotes |
| JP6360039B2 (ja) | 2012-05-03 | 2018-07-18 | カラ ファーマシューティカルズ インコーポレイテッド | 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 |
| CN104519867A (zh) | 2012-05-11 | 2015-04-15 | 希普拉有限公司 | 药物组合物 |
| EA201492096A1 (ru) | 2012-05-14 | 2015-08-31 | Айновиа, Инк. | Устройство и способы применения капельного генератора с ламинарным течением |
| SG10201602609XA (en) | 2012-05-15 | 2016-05-30 | Eyenovia Inc | Ejector devices, methods, drivers, and circuits therefor |
| US20150297800A1 (en) | 2012-07-03 | 2015-10-22 | Sio2 Medical Products, Inc. | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS |
| US9827250B2 (en) | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| EP2887923B1 (en) | 2012-08-24 | 2023-04-05 | Sun Pharmaceutical Industries Limited | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
| US9498035B2 (en) | 2012-12-21 | 2016-11-22 | Coopervision International Holding Company, Lp | Silicone hydrogel contact lenses for sustained release of beneficial polymers |
| WO2014140105A1 (en) | 2013-03-13 | 2014-09-18 | D2 Bioscience Group Ltd. | Materials and compositions for dental cements and filler materials |
| EP2978453B1 (en) | 2013-03-29 | 2018-10-31 | Onefocus Technology, LLC | Drug delivery from contact lenses with a fluidic module |
| ES2871116T3 (es) | 2013-05-06 | 2021-10-28 | Kaohsiung Chang Gung Memorial Hospital | Composición farmacéutica de un AINE y atropina |
| PL3231801T3 (pl) | 2013-05-17 | 2019-07-31 | Incyte Corporation | Sol bipirazolu jako inhibitor jak |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| DE102013218802B4 (de) | 2013-09-19 | 2018-06-28 | Aero Pump Gmbh | Abgabevorrichtung für Fluide aus einem Fluidbehälter |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US20160009705A1 (en) | 2014-06-24 | 2016-01-14 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| EP3179975A4 (en) | 2014-08-13 | 2018-04-18 | University of Florida Research Foundation, Inc. | Preservative removal from eye drops |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| DE102015104646B3 (de) | 2015-03-26 | 2016-06-30 | Aero Pump Gmbh | Abgabevorrichtung für ein Fluid |
| WO2016196367A1 (en) | 2015-05-29 | 2016-12-08 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| ES2929368T3 (es) | 2016-05-25 | 2022-11-28 | Singapore Health Serv Pte Ltd | Composición acuosa que contiene atropina |
| CA3029281A1 (en) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| ES2957459T3 (es) | 2016-09-19 | 2024-01-19 | Mexichem Fluor Sa De Cv | Composición farmacéutica que comprende glicopirrolato |
| AU2018224426B2 (en) | 2017-02-21 | 2023-05-18 | Singapore Health Services Pte Ltd | Composition and method for preventing or delaying onset of myopia comprising atropine |
| CN110621298B (zh) | 2017-05-11 | 2022-12-20 | 维卢玛有限公司 | 阿托品药物组合物 |
| CA3070556A1 (en) | 2017-07-20 | 2019-01-24 | Alan Laboratories, Inc. | Compositions and methods for treatment of myopia |
| WO2019104191A1 (en) | 2017-11-21 | 2019-05-31 | Sydnexis, Inc. | Ophthalmic composition and delivery device thereof |
| US20230041788A1 (en) | 2019-12-16 | 2023-02-09 | Sydnexis, Inc. | Ophthalmic compositions comprising d2o |
-
2015
- 2015-05-29 US US14/726,139 patent/US9421199B2/en active Active
- 2015-06-23 JP JP2016574898A patent/JP6678362B2/ja active Active
- 2015-06-23 BR BR112016030368-7A patent/BR112016030368B1/pt active IP Right Grant
- 2015-06-23 CN CN201910968378.3A patent/CN110638749A/zh active Pending
- 2015-06-23 SG SG11201610682UA patent/SG11201610682UA/en unknown
- 2015-06-23 WO PCT/US2015/037249 patent/WO2015200361A1/en active Application Filing
- 2015-06-23 RS RS20220765A patent/RS63486B1/sr unknown
- 2015-06-23 PT PT158118653T patent/PT3160471T/pt unknown
- 2015-06-23 HR HRP20220972TT patent/HRP20220972T1/hr unknown
- 2015-06-23 HU HUE15811865A patent/HUE059521T2/hu unknown
- 2015-06-23 CN CN202210803133.7A patent/CN115192520A/zh active Pending
- 2015-06-23 CN CN201580045735.9A patent/CN106572998B/zh active Active
- 2015-06-23 EP EP20159621.0A patent/EP3689350A1/en active Pending
- 2015-06-23 PL PL15811865.3T patent/PL3160471T3/pl unknown
- 2015-06-23 CA CA2953363A patent/CA2953363C/en active Active
- 2015-06-23 SG SG10201913976SA patent/SG10201913976SA/en unknown
- 2015-06-23 KR KR1020177002056A patent/KR102506109B1/ko active IP Right Grant
- 2015-06-23 KR KR1020197038476A patent/KR20200001612A/ko not_active IP Right Cessation
- 2015-06-23 KR KR1020217029081A patent/KR102710491B1/ko active IP Right Grant
- 2015-06-23 LT LTEPPCT/US2015/037249T patent/LT3160471T/lt unknown
- 2015-06-23 SI SI201531871T patent/SI3160471T1/sl unknown
- 2015-06-23 EP EP22175801.4A patent/EP4115884A1/en active Pending
- 2015-06-23 SG SG10201707617VA patent/SG10201707617VA/en unknown
- 2015-06-23 DK DK15811865.3T patent/DK3160471T3/da active
- 2015-06-23 KR KR1020247031630A patent/KR20240144477A/ko unknown
- 2015-06-23 ES ES15811865T patent/ES2924243T3/es active Active
- 2015-06-23 EP EP15811865.3A patent/EP3160471B1/en active Active
- 2015-06-24 TW TW112131152A patent/TW202412797A/zh unknown
- 2015-06-24 TW TW104120379A patent/TWI763620B/zh active
-
2016
- 2016-04-25 US US15/568,381 patent/US10842787B2/en active Active
- 2016-07-12 US US15/208,537 patent/US9770447B2/en active Active
- 2016-12-19 IL IL249643A patent/IL249643B/en unknown
-
2017
- 2017-07-27 US US15/661,816 patent/US10076515B2/en active Active
-
2018
- 2018-02-13 US US15/895,933 patent/US10201534B2/en active Active
- 2018-12-18 US US16/224,286 patent/US10864208B2/en active Active
-
2020
- 2020-01-30 JP JP2020014108A patent/JP7505888B2/ja active Active
- 2020-11-13 US US17/097,930 patent/US11596625B2/en active Active
-
2022
- 2022-01-12 JP JP2022003408A patent/JP2022062045A/ja active Pending
- 2022-11-16 US US18/055,945 patent/US11896588B2/en active Active
- 2022-11-16 US US18/055,940 patent/US11890277B2/en active Active
- 2022-11-16 US US18/055,949 patent/US11883390B2/en active Active
-
2023
- 2023-10-19 JP JP2023180519A patent/JP2024050526A/ja active Pending
- 2023-12-14 US US18/539,823 patent/US20240165098A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522292A5 (ja) | ||
| JP2018521000A5 (ja) | ||
| CA3045733A1 (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| JP2013526572A5 (ja) | ||
| JP6968457B2 (ja) | 選択された抗コリン作動性両性イオンの使用 | |
| RU2018106453A (ru) | Соединения | |
| JP2016106150A5 (ja) | ||
| HRP20220972T1 (hr) | Oftalmološki pripravci koji sadrže muskarinski antagonist i deuteriranu vodu | |
| JP2011520805A5 (ja) | ||
| JP2015025011A5 (ja) | ||
| KR20190013877A (ko) | 아트로핀-함유 수성 조성물 | |
| JP2016512558A5 (ja) | ||
| JP2014506927A5 (ja) | ||
| TWI832920B (zh) | 抑制軟性隱形眼鏡變質之眼科用組成物 | |
| JP2013542247A5 (ja) | ||
| JP2011516477A5 (ja) | ||
| RU2015144083A (ru) | Комбинация лекарственных средств | |
| ES2341789T3 (es) | Composiciones oftalmicas y metodos de uso de las mismas. | |
| JP2013525493A5 (ja) | ||
| KR20180095928A (ko) | 노안의 치료를 위한 조성물 | |
| JP2013534527A5 (ja) | ||
| JP2013515739A5 (ja) | ||
| JP2013500977A5 (ja) | ||
| JP2018532806A5 (ja) | ||
| RU2014148758A (ru) | Офтальмологические композиции с улучшенной защитой от обезвоживания и удерживанием |